XEN ® -63 Compared to XEN ® -45 Gel Stents to Reduce Intraocular Pressure in Glaucoma.

Autor: Evers C; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Böhringer D; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Kallee S; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Keye P; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Philippin H; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.; International Centre for Eye Health, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK., Piotrowski T; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Reinhard T; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Lübke J; Eye Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2023 Jul 31; Vol. 12 (15). Date of Electronic Publication: 2023 Jul 31.
DOI: 10.3390/jcm12155043
Abstrakt: The XEN ® gel stent reduces intraocular pressure (IOP) in glaucoma. XEN ® -45 is widely used; the newer XEN ® -63 has a larger lumen targeting potentially lower IOP outcomes. We retrospectively compared the first 15 XEN ® -63 cases to 15 matched XEN ® -45 controls. With a preoperative IOP of 18.1 ± 3.9 mmHg (mean ± SD) and a final IOP of 9.1 ± 2.0 mmHg, XEN ® -63 implantation resulted in an IOP reduction of 44.6 ± 16.5%. Similarly, with a preoperative IOP of 18.3 ± 4.5 mmHg and a final IOP of 10.3 ± 2.1 mmHg, XEN ® -45 implantation resulted in an IOP reduction of 40.1 ± 17.2%. The median follow-up period was 204 days (range 78-338 days) for the XEN ® -63 group and 386 days (range 99-1688 days) for the XEN ® -45 group. In total, 5/15 eyes of each group underwent open conjunctival bleb revision within the period of observation. Three eyes of the XEN ® -63 group had secondary glaucoma surgery. One eye in the XEN ® -63 group and three eyes in the XEN ® -45 group required a restart of antiglaucomatous medication. In conclusion, both stents effectively lower IOP and medication. XEN ® -63 achieved a slightly lower IOP over a short follow-up. Complication and revision rates were similar.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje